Using HRR proficient pancreatic cancer cells for discovery, investigators have shown that a small molecule disruptor of the BRCA2-RAD51 relationship sensitised cells to olaparib at a level comparable to BRCA2 mutated cells [175]. The gene discussed is BRCA2; the disease is familial pancreatic carcinoma.